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EDITORIAL
Of mice and men: Murine models of anti-GBM
antibody nephritis
The autoimmune response to renal antigens is a sig- merulonephritis. While GBM contains the 1 to 5(IV)
collagen chains, subsequent studies have shown that onlynificant cause of progressive glomerulonephritis and end-
stage renal disease, leading to dialysis or kidney trans- the fraction containing the 3 to 5(IV) NC1 domains
is nephritogenic. Recently, heterologuos (human) or ho-plantation. A prominent target of renal immune injury
is type IV collagen, a major constituent of the glomerular mologuos (rat) recombinant 3(IV) NC1 domains were
shown to induce anti-GBM antibody disease in rats,basement membrane (GBM). Type IV collagen is a fam-
ily of six chains (1 to 6) that assemble into several firmly establishing that the autoantigen implicated in the
human disease is also pathogenic in the correspondingdistinct supramolecular networks with different chain
compositions and a tissue-specific distribution. In anti- animal models [2, 3].
Although historically numerous species were used asGBM antibody nephritis, pathogenic autoantibodies are
directed against the non-collagenous (NC1) domain of the animal models of anti-GBM antibody nephritis, the
Wystar-Kyoto strain of rats has been used almost exclu-3 (IV) chain, also known as the “Goodpasture (auto)
antigen” [1]. In the GBM, the 3(IV) chain is a com- sively for these studies in the last decade. The rat model
exhibits many features similar to human disease, includ-ponent of the 3 · 4 · 5(IV) collagen network that is
required for the long-term stability of the renal ultrafil- ing the presence of serum circulating anti-GBM antibod-
ies, the renal pathology, and pulmonary involvement [4].tration barrier. Binding of pathogenic autoantibodies to
the GBM causes rapidly progressive glomerulonephritis, Despite widespread use of mice as models for other
autoimmune diseases, they have been used relativelywhich has a fatal outcome in about half of the patients if
not treated. However, the prognostic is good if the disease infrequently as models for anti-GBM antibody nephritis.
An unsurpassed advantage of the mouse system is theis diagnosed early and treated promptly by plasmaphere-
sis—to remove the pathogenic antibodies—and immuno- availability of numerous transgenic lines and the relative
suppression. In some patients, autoantibodies may also ease in engineering new ones, which gives the experi-
bind to the alveolar basement membrane, causing pul- menter a powerful tool. This is well illustrated in this
monary hemorrhage, a clinical picture known as Good- issue of Kidney International by the report of Meyers et
pasture syndrome (or Goodpasture disease). al [5], who induced anti-GBM nephritis in the Xeno-
The delineation of pathogenic mechanisms in anti- Mouse II, a transgenic mouse that produces human IgG2.
GBM nephritis has benefited greatly from the availability XenoMouse strains carry portions of the human immu-
of appropriate animal models, developed over the past noglobulin heavy and light (kappa) chains loci, including
four decades. Anti-GBM antibody nephritis can be in- the variable regions, in a germ-line configuration, but
duced in animals actively, by immunization with certain are deficient in production of murine immunoglobulins.
type IV collagen preparations, or passively, by transfer Meyers et al immunized XenoMouse II animals with
of anti-GBM antibodies. The choice of the nephritogenic three forms of 3(IV) NC1 domains, including bovine
antigen in the active immunization models closely paral- 3(IV) NC1 dimers and recombinant human 3(IV)
leled the existing knowledge about the identity of the NC1 monomers expressed in Escherichia coli and kidney
human GBM autoantigen. Early studies, like the pio- 293 cells. All immunized mice produced anti-GBM anti-
neering work by Steblay on sheep, used relatively crude bodies that deposited along the GBM in a linear pattern
preparations of GBM. After the identification of the NC1 and caused severe proliferative glomerulonephritis. The
domain of the 3(IV) collagen chain as the Goodpasture pathologic findings included proteinuria, elevated serum
autoantigen [1], purified NC1 domains solubilized from creatinine, and, in some animals, pulmonary hemor-
the GBM by collagenase digestion became the antigen rhage. The study further supports the importance of
of choice for induction of experimental autoimmune glo- 3(IV) NC1 domain in the pathogenesis of anti-GBM
disease and represents the first use of the XenoMouse
as an animal model for a human autoimmune disease.Key words: glomerular basement membrane (GBM); anti-GBM anti-
Meyers et al further demonstrate the central patho-body nephritis; experimental autoimmune glomerulonephritis; Good-
pasture syndrome; type IV collagen; autoantibodies. genic role of anti-GBM antibodies by passive transfer
experiments. A human monoclonal antibody of the Ig2 2002 by the International Society of Nephrology
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subclass was cloned from a XenoMouse animal immu- tablishment of animal models of anti-GBM antibody ne-
phritis that mimic the epitope specificity of human auto-nized with bovine 3 dimers. This monoclonal antibody,
antibodies will not only advance knowledge of thetermed mAb F1.1, was specific to 3 (IV) NC1 and was
human disease, but will be uniquely suited for testingcapable to transfer the disease to naive XenoMouse
novel therapeutic approaches that target specifically thehosts. Mice injected with mAb F1.1 developed pro-
pathogenic autoantibodies.teinuria and mild proliferative nephritis associated with
human IgG deposition. Characterization of mAb F1.1 Dorin-Bogdan Borza and Billy G. Hudson
Kansas City, Kansas, USAshowed it shares idiotypes with anti-GBM antibodies
from human patients. However, unlike anti-GBM anti- Correspondence to Billy G. Hudson, Ph.D., Department of Biochem-
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